Evidence map›Paper›PMID 36703972›Full record

ArticleFrontiers in immunology2022

Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation.

Xiaohe Zhou, Mingli Jiang, Fengjie Wang, Yuan Qian, Qinwei Song, Yu Sun, Runan Zhu, Fang Wang, Dong Qu, Ling Cao and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xiaohe ZhouLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Mingli JiangLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Fengjie WangLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Yuan QianLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Qinwei SongClinical Laboratory, Affiliated Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Yu SunLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Runan ZhuLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Fang WangLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Dong QuIntensive Care Unit, Affiliated Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Ling CaoDepartment of Respiratory, Affiliated Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Lijuan MaClinical Laboratory, Affiliated Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Yanpeng XuLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Ri DeLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Linqing ZhaoLaboratory of Virology, Capital Institute of Pediatrics, Beijing, China.
Capital Institute of Pediatrics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Immune escaping from host herd immunity has been related to changes in viral genomic sequences. The study aimed to understand the diverse immune responses to different subtypes or genotypes of human respiratory syncytial virus (RSV) in pediatric patients. Methods: The genomic sequences of different subtypes or RSV genotypes, isolated from Beijing patients, were sequenced and systematically analyzed. Specifically, the antiviral effects of Palivizumab and the cross-reactivity of human sera from RSV-positive patients to different subtypes or genotypes of RSV were determined. Then, the level of 38 cytokines and chemokines in respiratory and serum samples from RSV-positive patients was evaluated. Results: The highest nucleotide and amino acid variations and the secondary and tertiary structure diversities among different subtypes or genotypes of RSV were found in G, especially for genotype ON1 with a 72bp-insertion compared to NA1 in subtype A, while more mutations of F protein were found in the NH-2 terminal, including the antigenic site II, the target of Palivizumab, containing one change N276S. Palivizumab inhibited subtype A with higher efficiency than subtype B and had stronger inhibitory effects on the reference strains than on isolated strains. However, RSV-positive sera had stronger inhibitory effects on the strains in the same subtypes or genotypes of RSV. The level of IFN-α2, IL-1α, and IL-1β in respiratory specimens from patients with NA1 was lower than those with ON1, while there were higher TNFα, IFNγ, IL-1α, and IL-1β in the first serum samples from patients with ON1 compared to those with BA9 of subtype B. Conclusions: Diverse host immune responses were correlated with differential subtypes and genotypes of RSV in pediatric patients, demonstrating the impact of viral genetics on host immunity.

Indexed as

Immune EvasionRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsChildGenotypeHumansInterleukin-1alphaPalivizumabPhylogenyInterleukin-1alphaPalivizumabantiviral effectschemokines and cytokineshuman respiratory syncytial virusimmune evasionviral genetic differences

Identifiers

PMID36703972
PMCPMC9871593
OpenAlexW4315433943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.